Notification That Quarterly Report Will Be Submitted Late (nt 10-q)
May 12 2020 - 06:06AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
|
SEC
FILE NUMBER
000-26372
|
FORM
12b –25
NOTIFICATION
OF LATE FILING
|
CUSIP
NUMBER
00547W208
|
Check
One:
☐
Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form
10-D ☐ Form N-CSR
For
Period Ended: March 31, 2020
☐
Transition
Report on Form 10-Q
☐
Transition
Report on Form 20-F
☐
Transition
Report on Form 11-K
☐
Transition
Report on Form 10-Q
☐
Transition
Report on Form N-SAR
For
the Transition Period Ended: __________________________
If
the notification relates to a portion of the filing check above, identify the Item(s) to which the notification relates:
PART
I -- REGISTRANT INFORMATION
Adamis
Pharmaceuticals Corporation
|
Full Name of Registrant
|
|
Former Name if
Applicable
|
11682
El Camino Real, Suite 300
|
Address of Principal
Executive Office (Street and Number)
|
San
Diego, CA 92130
|
City, State and
Zip Code
|
PART
II -- RULES 12b - 25(b) and (c)
|
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule
12b - 25(b), the following should be completed. (Check box if appropriate.)
|
|
(a)
|
The
reasons described in reasonable detail in Part III of this form could not be eliminated
without unreasonable effort expense;
|
|
☒
|
(b)
The subject annual report, semi-annual report, transition report on Form 10-Q, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or a portion thereof will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or subject distribution report on Form 10-D, or a portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
|
|
☐
|
(c)
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
State below in reasonable detail the reasons why Forms 10-K, 20-F,
11-K, 10-Q, N-SAR, N-CSR, or the transition report or portion thereof could not be filed within the prescribed time period. (Attach
extra sheets if needed.)
Adamis Pharmaceuticals Corporation (the
“Registrant” or the “Company”) is filing this Notification of Late Filing on Form 12b-25 with respect
to its Quarterly Report on Form 10-Q for the three months ended March 31, 2020 (the “Form 10-Q”) because it needs
additional time to prepare and review certain information and complete its review of its financial statements and other
disclosures in the Form 10-Q, including without limitation regarding assessing the impact of subsequent events and impairment
of its goodwill and indefinite-lived intangible assets and the procedures related thereto, which could not be completed by
the date required without incurring unreasonable effort and expense. The Company anticipates that it will file its Form 10-Q
as soon as reasonably possible and within the 5-day grace period provided by Rule 12b-25 of the Securities Exchange Act of
1934, as amended.
PART
IV – OTHER INFORMATION
|
|
(1)
|
Name
and telephone number of person to contact in regard to this notification.
|
|
Robert O. Hopkins
|
(858) 997-2400
|
|
(Name)
|
(Area
Code and Telephone Number)
|
|
(2)
|
Have
all other periodic reports required under section 13 or 15(d) of the Securities Exchange
Act of 1934 or section 30 of the Investment Company Act of 1940 during the preceding
12 months or for such shorter period that the registrant was required to file such report(s)
been filed? If the answer is no, identify report(s).
|
☒
Yes ☐ No
|
(3)
|
Is
it anticipated that any significant change in results of operations from the corresponding
period for the last fiscal year will be reflected by the earnings statements to be included
in the subject report or portion thereof?
|
☒
Yes ☐ No
For the reasons stated above in Part III, the Company cannot
reasonably estimate at this time the anticipated change to its results of operations, but it expects the Company’s
revenue to decrease, and its net loss to increase, compared to the corresponding period for the last fiscal year ended March
31, 2019.
Adamis Pharmaceuticals Corporation
|
(Name
of Registrant as specified in its charter)
|
has
caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.
Date: May 11, 2020
|
By:
|
/s/ ROBERT O. HOPKINS
|
|
|
Robert O. Hopkins
|
|
|
Chief Financial Officer
|
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Feb 2024 to Mar 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Mar 2023 to Mar 2024